Rayno Life Science Stocks Having A Nice Q1 Ending Run
Well known Large Caps Dominate
Rayno focus stocks that are running up 2% + today: AMGN, AMRI, ASTX, BIIB, GILD, QGEN, and REGN. The Biopharma sector is outperforming Tools and Dx for Q1. Tools and DX winners for the week are ALR, ILMN, and NEOG.
With most well known large and mid- cap biotechs over-owned and up big, the time has come to find new mid and small cap stocks that are undervalued. One $$Billion is the new market cap target for mid-cap biopharma stocks that have emerging Phase 2 pipelines.These smaller cap stocks are up this week on news:
Array Pharmaceuticals (ARRY $4.95) up 21.8% for week; small molecule drugs for cancer and inflammation.
EndoCyte (ECYT $12.60) up 28% for week; SMDCs for targeted therapy for cancer and inflammation.
Repros Therapeutics (RPRX $16.16) up 71.5% today!; treatment of hypogonadism.
IBB hits new high today near $160, up 16.3% for Q1. Also the broad based Healthcare ETF XLV is up 15% YTD.